A single 25 mg dose of psilocybin, but not 10 mg, reduced depression scores more than a 1 mg control dose over three weeks in adults with treatment-resistant depression. In this phase 2 trial, 233 participants were randomly assigned to 25 mg, 10 mg, or 1 mg of synthetic psilocybin with psychological support. The 25 mg group showed an average 12-point drop on the MADRS depression scale versus a 5.4-point drop in the 1 mg group, a significant difference. The 10 mg group did not differ significantly from control. Response and remission rates at three weeks supported the primary result, but sustained response at 12 weeks was not significantly different.
Dutch mental health professionals hold generally positive attitudes toward psychedelic-assisted psychotherapy (PAP) for conditions like PTSD and major depression, according to a survey of 198 clinicians. Positive attitudes were associated with clinicians' own prior use of MDMA or psilocybin. Respondents considered psychiatrists and licensed psychologists the most suitable professionals to administer PAP, expressed concerns about maintaining therapeutic connection during patients' altered states, and preferred that PAP be delivered in specialized hospital-based facilities. The findings point to implementation needs, including targeted training and clear clinical guidelines.